Report shows poverty influences UK survival rates for treatable leukaemia

February 4, 2014 by David Garner

Patients from less affluent backgrounds have a greater chance of dying from a form of chronic blood cancer than those from more affluent areas, according to a comprehensive study carried out by researchers at the University of York.

For the 500 people diagnosed with chronic myeloid leukaemia (CML) each year in the UK, the introduction of (TKI) drugs a decade ago, taken as daily oral pills, turned this once fatal cancer into a manageable condition with a near normal life-span.

The new study, funded by the charity Leukaemia & Lymphoma Research and published online in BMJ Open, found that, despite equal access to the same clinical care and treatment, survival rates were significantly lower for patients living in more deprived areas.

Based in Yorkshire and Humberside and covering a population of 3.6 million, the research was undertaken by the Haematological Malignancy Research Network (HMRN). HMRN, a collaborative project between NHS clinicians and researchers in the Department of Health Sciences at York, gathers detailed information from 14 hospitals on every blood cancer patient's diagnosis, treatment and outcome.

The life-span of patients with CML diagnosed between 2004 and 2011 was similar to that reported from clinical trials – 90 per cent survived their leukaemia for five years or more – and this was the same in older and younger patients. However, using a standard measure of deprivation, the researchers found statistically significant inequalities – around 95 per cent of CML patients from the most affluent groups were alive after five years, compared with just 80% of those from more deprived groups. Approximately 40 per cent of all patients lived in less affluent areas, yet this group accounted for 60 per cent of the deaths.

TKI therapy is life-long, requiring medication to be taken at set times each day, as well as regular out-patient appointments to monitor patients' response and well-being. The study authors believe that issues related to these factors could explain the difference in survival rates between social groups.

Dr Alex Smith, from the Department of Health Sciences at York, who led the research said: "These findings highlight the importance of conducting comprehensive population-based studies to examine treatment pathways across the entire patient population, rather than solely concentrating on findings from ."

Dr Russell Patmore, consultant haematologist and medical director for clinical support services at the Queens Centre for Oncology, said: "Modern treatment of CML has changed a disease that was usually fatal into a condition that can be easily and simply managed by oral medication. Treatment has been so successful that most patients can now expect to lead a normal life, and its therefore concerning that some are benefitting less than others.

"We suspect a major factor is that we are not supporting patients sufficiently to allow them to be fully compliant with a treatment that needs to be taken every day to be effective. We would encourage all teams treating patients with CML to use these findings to focus their resource where it is likely to be most beneficial. This includes helping patients to manage their CML by explaining fully the importance of daily treatment and providing easy access to ongoing support."

Dr Matt Kaiser, Head of Research at Leukaemia & Lymphoma Research, said: "The vast majority of patients diagnosed with CML in the UK are now living a near normal life, thanks to these new drugs that are freely available on the NHS. This study gives invaluable insight into real life issues that affect patients. To give patients the best chance of long-term survival and quality of life, we need to confirm whether some patients may be dying because they are not taking their tablets regularly. This would be crucial in guiding what support need and how we can give it most effectively."

Explore further: Improved treatments for chronic myeloid leukaemia have dramatically increased survival

More information: "Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort." Smith AG, Painter D, Howell DA, Evans P, Smith G, Patmore R, Jack A, Roman E. BMJ Open. 2014 Jan 15;4(1):e004266. DOI: 10.1136/bmjopen-2013-004266.

Related Stories

Improved treatments for chronic myeloid leukaemia have dramatically increased survival

December 12, 2012
Survival for people diagnosed with Chronic Myeloid Leukaemia (CML) has risen by nearly half, with around 58 per cent of people surviving their disease for at least five years compared with only around 40 per cent in the late ...

Study identifies new drug target in deadly form of leukemia

June 3, 2013
A research team led by the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore has identified ways to inhibit the function of a key protein linked to stem cell-like behavior in terminal-stage chronic myeloid leukemia ...

Battling defiant leukemia cells

October 7, 2013
Two gene alterations pair up to promote the growth of leukemia cells and their escape from anti-cancer drugs, according to a study in The Journal of Experimental Medicine.

Quality-of-life issues need to be addressed for CML patients, researchers say

June 10, 2013
Researchers at Moffitt Cancer Center have determined that chronic myeloid leukemia patients who are treated with a class of oral chemotherapy drugs known as a tyrosine kinase inhibitors have significant side effects and quality-of-life ...

Poorest bowel cancer patients more likely to die within month of surgery

June 14, 2012
(Medical Xpress) -- Bowel cancer patients living in the most deprived areas are 24 per cent more likely to die within five years of treatment than their more affluent neighbours and this difference appears to be a result ...

Ponatinib active in CML, ph+ acute lymphoblastic leukemia

November 5, 2013
(HealthDay)—Ponatinib is active in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL), according to a study published online Nov. 1 in the New England Journal ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.